天津医药

天津医药 ›› 2021, Vol. 49 ›› Issue (11): 1211-1215.doi: 10.11958/20210761

• 应用研究 • 上一篇    下一篇

一种基于体内CTC捕获的CellCollector®技术对乳腺癌患者分层的价值

王玲艳，高春晖，冯雪园，崔鑫淼，孙建云，何向辉   

  1. 1天津医科大学总医院普外科（邮编300052）；2保定市第一中心医院乳腺外科
  • 收稿日期:2021-03-30 修回日期:2021-07-05 出版日期:2021-11-15 发布日期:2021-11-19

The value of CellCollector® in vivo CTC capture technology for stratification of breast cancer patients

WANG Ling-yan, GAO Chun-hui, FENG Xue-yuan, CUI Xin-miao, SUN Jian-yun, HE Xiang-hui   

  1. 1 Department of General Surgery, Tianjin Medical University General Hospital, Tianjin 300052, China; 2 Department of Breast Surgery, Baoding First Central Hospital
  • Received:2021-03-30 Revised:2021-07-05 Published:2021-11-15 Online:2021-11-19

PDF (PC)

2828

摘要： 目的　探讨基于CellCollector®技术捕获的循环肿瘤细胞（CTC）用于筛选转移风险较高的乳腺癌患者的可能性。方法　入组60例原发性乳腺癌患者为乳腺癌组，其中Ⅰ期16例、Ⅱ期29例、Ⅲ期11例、Ⅳ期4例。通过CellCollector®进行至少1次外周血CTC检测，并随访4～19个月。同时入组10例健康女性志愿者作为对照组，仅进行1次CTC检测。分析不同年龄、绝经情况、TNM分期、分子分型、Ki-67表达程度患者CTC阳性率的差异。结果　乳腺癌组基线CTC检出率为73.33%；Ⅰ~Ⅳ期检出率分别为43.75%、82.76%、81.82%和100%，不同临床分期下CTC检出率差异有统计学意义。不同年龄、是否绝经、不同分子分型及Ki-67表达程度患者CTC检出率差异均无统计学意义。24例行2次CTC检测。4例疾病进展患者中，1例CTC数目增多；20例无疾病进展患者中，3例CTC数目增加。CTC数目动态变化与疾病进展不存在相关性。结论　CellCollector®体内CTC检测技术在非转移性乳腺癌中检出率较高，为CTC筛选转移风险较高的乳腺癌患者提供了可能。

关键词: 乳腺肿瘤, 肿瘤细胞, 循环, CellCollector?, 体内检测, 动态监测

Abstract: Objective　To explore the possibility of using circulating cancer cells (CTC) captured by CellCollector® technology for screening breast cancer patients with higher risk of metastasis. Methods　Sixty patients with primary breast cancer were enrolled as the breast cancer group, including 16 in stage Ⅰ, 29 in stage Ⅱ, 11 in stage Ⅲ and 4 in stage Ⅳ. Patients were tested for at least one CTC detection through CellCollector® and followed up for 4-19 months. At the same time, 10 healthy female volunteers were enrolled as the control group, and only one CTC test was performed. The CTC positive rates in patients with different age, menopause, TNM stage, molecular typing and Ki-67 expression were analyzed. Results　The baseline CTC detection rate of breast cancer patients was 73.33%. The detection rates of Ⅰ-Ⅳ stage were 43.75%, 82.76%, 81.82% and 100%, respectively. There were significant differences in the detection rates of CTC under different clinical stages ( P＜0.05). There were no significant differences in CTC detection rates in patients with different age, menopause, molecular typing and Ki-67 expression. Among the 24 patients received twice CTC tests, the number of CTC increased in 1 of the 4 patients with disease progression. Of the 20 progression-free patients, the number of CTC increased in 3 patients, and there was no correlation between the dynamic changes of CTC number and disease progression. Conclusion　The detection rate of CellCollector® in vivo CTC is higher in non metastatic breast cancer. It is possible for CTC to screen patients with breast cancer with higher metastatic risk.

Key words: breast neoplasms, neoplastic cells, circulating, CellCollector?, in vivo detection, dynamic monitoring